ChemicalBook > CAS DataBase List > Gatralimab
Gatralimab
- Product Name
- Gatralimab
- CAS No.
- 1826020-80-7
- Chemical Name
- Gatralimab
- Synonyms
- Gatralimab;Gatralimab (anti-CD52);Research Grade Gatralimab;Research Grade Gatralimab(DHD95102)
- CBNumber
- CB28081171
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Gatralimab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Gatralimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Gatralimab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
- Tel
- 400-668-6834
- info@selleck.cn
- Country
- China
- ProdList
- 6071
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
- Tel
- 025-58649515
- Country
- CHINA
- ProdList
- 190
- Advantage
- 58
- Tel
- 18312220236
- Country
- CHINA
- ProdList
- 178
- Advantage
- 58
1826020-80-7, GatralimabRelated Search:
Marstacimab
Tilavonemab
Abituzumab
Nesvacumab
Plozalizumab
Narlumosbart
Gemtuzumab
Evinacumab
Ontuxizumab
Evolocumab